It is not so much that they wanted a second opinion as much as they wanted to confirm what Genta presented to the FDA with a bigger sample and somewhat they way the information was presented..IMO i believe that those who stay aboard should be very happy. I mean people need to look at some obvious items here. The big negative item is that none of the biger pharmas have tried to buy this..surely they can interperut things the way i or you do and have not bought a potenitally promising pipeline for free (in terms of big pharma budgets .01/share is free)
With that being the negative there is also a ton of positives here: -they (GNTA) have put a ton of effort into re-submitting to fda -the advisors for the panel that gnta have selected are top notch -the whole change over to a different derver (not a huge deal but worth looking at) -remember if these uppper Mgmt dilute and issue more shares it also hurts their own portfolios---why do this unless you truly believed in something.
GUYS you are going to miss a ride that many people read and hope for but rarely come across...again In my opinnion. For the thousand dollare present you wife or girlfriend did not appreciate you could set yourself up with a lottery ticket that has much better odds than scratching a coin.
Market Data 
Markets 
AI
